This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Infectious disease				
Viral infection	Protein tyrosine phosphatase 1B (PTP-1B; PTPN1)	<p>Cell culture and feline studies suggest PTP-1B inhibitors could increase the efficacy of interferon (IFN) therapies against viral infections. In cultured cells infected with HCV or vesicular stomatitis virus, type 1 interferon (IFN1) plus the PTP-1B inhibitor 7-CBNP decreased viral replication compared with IFN1 alone. In cats with chronic infection of feline calicivirus, submucosal injection of 7-CBNP decreased inflammation compared with that seen prior to treatment. Next steps include using 7-CBNP or other PTP-1B inhibitors in nonmouse models of viral infection, including HIV-related feline immunodeficiency virus (FIV).</p> <p>TransTech Pharma Inc.'s PTP-1B inhibitor, TTP814, is in Phase II testing to treat diabetes.</p> <p>Isis Pharmaceuticals Inc.'s ISIS-PTP1bRx, a PTP-1B antisense oligonucleotide, is in Phase I testing to treat diabetes.</p> <p>Ohr Pharmaceutical Inc.'s trodusquemine (MSI-1436), a small molecule PTP-1B inhibitor, is in Phase I testing for the same indication.</p> <p>SciBX 5(46); doi:10.1038/scibx.2012.1210 Published online Nov. 29, 2012</p>	Patented; available for licensing	<p>Carbone, C.J. <i>et al. Proc. Natl. Acad. Sci. USA</i>; published online Nov. 5, 2012; doi:10.1073/pnas.1211491109</p> <p>Contact: Serge Y. Fuchs, University of Pennsylvania, Philadelphia, Pa. e-mail: syfuchs@vet.upenn.edu</p>